Aspen Pharmacare sells European rights to Ovestin to Ennogen for €197m

Aspen Pharmacare (seller) / Ennogen Healthcare International (buyer)


Lead party: Ennogen Healthcare International (buyer)

Coverage: The Meridian legal market record (editorial).

JSE-listed Aspen Pharmacare has agreed to sell the European commercialisation rights and related intellectual property for Ovestin, its oestriol-based women’s health product, to Ennogen Healthcare International for €197m (c. US$220m). Ovestin inventory of about €4m transfers in addition.

Aspen will manufacture and supply the active ingredient and finished cream for Europe for at least ten years, provide strategic support for five years at €1m a month, and offer transitional services for up to three years. Aspen describes the sale as unlocking value from non-core assets to redeploy capital towards emerging markets, with share buybacks its preferred means of returning proceeds.

Advisers: not disclosed.

Status: announced; completion timing not disclosed.

Sources: HealthcareMEA, 3 November 2026; Reuters via Yahoo Finance, 2 November 2026.